Evidence map›Paper›PMID 42240763›Full record

ArticleMolecular diversity2026

Discovery, synthesis, and anti-cancer activity of N-CF

Qigang Sun, Jia-Yi Li, Qingjiang Li, Yu Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qigang Sun *Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, China.
Jia-Yi Li *State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Qingjiang LiState Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. liqingj3@mail.sysu.edu.cn.
Yu ZhangSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China. zyu-708@foxmail.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2026A1515011220 and 2024A1515012178Hainan Provincial Natural Science Foundation of China 825MS158Hunan Provincial Natural Science Foundation of China 2024JJ6397National Natural Science Foundation of China 22571327 and 22171293
6 · The paper itself

Abstract

Benzimidazole is a privileged heterocyclic pharmacophore widely used in medicinal chemistry, while the N-trifluoromethyl (N-CF

Indexed as

Antineoplastic AgentsBenzimidazolesDrug DiscoveryCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsBenzimidazolesanti-cancer activitybenzimidazoleN-CF3 moiety

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.